The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 07, 2025

Filed:

Mar. 30, 2021
Applicants:

The Broad Institute, Inc., Cambridge, MA (US);

Dana-farber Cancer Institute, Inc., Boston, MA (US);

The General Hospital Corporation, Boston, MA (US);

Inventors:

Nir Hacohen, Brookline, MA (US);

Catherine Ju-Ying Wu, Brookline, MA (US);

Edward F. Fritsch, Concord, MA (US);

Ute E. Burkhardt, Belmont, MA (US);

Assignees:
Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 35/17 (2025.01); A61K 40/11 (2025.01); A61K 40/32 (2025.01); A61K 40/42 (2025.01); A61K 40/46 (2025.01); C12N 15/10 (2006.01); C12Q 1/6881 (2018.01); G01N 33/569 (2006.01);
U.S. Cl.
CPC ...
C12Q 1/6881 (2013.01); A61K 39/0011 (2013.01); A61K 40/11 (2025.01); A61K 40/32 (2025.01); A61K 40/42 (2025.01); A61K 40/4201 (2025.01); A61K 40/46 (2025.01); C12N 15/1093 (2013.01); G01N 33/56972 (2013.01); A61K 2039/515 (2013.01); A61K 2039/572 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/16 (2013.01); G01N 2500/10 (2013.01);
Abstract

The present disclosure relates to methods for profiling subject specific and personalized T cell receptor (TCR) repertoires using a single-cell sequencing method. More particularly, disclosed are methods for determining binding of T cell receptors to subject specific neoantigens. In addition, the techniques herein may identify the antigenic targets of T cell receptors in the context of tumor neoantigens. Moreover, the present disclosure enables the discovery of T cell targets in numerous diseases, with implications for understanding the basic mechanisms of the mammalian immune response and for developing antigen-specific diagnostic markers and therapies. Finally, cloned TCRs can be used to formulate personalized immunotherapies for those inflicted with a disease, such as cancer.


Find Patent Forward Citations

Loading…